Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 9:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: renal denervation Clear all
Completed Not applicable Interventional

Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4

NCT01972139
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions
Renal Denervation using the Symplicity Renal Denervation System, Sham Renal Denervation, Renal Angiography
Device · Other
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia • Durham, North Carolina • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 11, 2026, 9:20 PM EDT
Terminated Not applicable Interventional Results available

Impact of Renal SympAthetic DenerVation on Chronic HypErtension

NCT01628198
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter
Device
Lead sponsor
Vivek Reddy
Other
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Sep 11, 2026, 9:20 PM EDT
Active, not recruiting Phase 3 Interventional

TARGET BP I Clinical Trial

NCT02910414
View directory record Official record
Conditions
Hypertension
Interventions
Dehydrated alcohol, Peregrine System Kit (Sham Procedure)
Drug · Device
Lead sponsor
Ablative Solutions, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Raleigh, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 11, 2026, 9:20 PM EDT
Active, not recruiting Not applicable Interventional

REDUCED 1 - Renal Denervation Using Ultrasonic Catheter EmitteD Energy Study /

NCT05372679
View directory record Official record
Conditions
Uncontrolled Stage 2 Hypertension
Interventions
Renal denervation
Device
Lead sponsor
SoniVie Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 11, 2026, 9:20 PM EDT
Completed Phase 3 Interventional

Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation

NCT01873352
View directory record Official record
Conditions
Atrial Fibrillation, Hypertension
Interventions
catheter ablation, renal sympathetic denervation
Procedure
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Network
Eligibility
18 Years to 75 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Short Hills, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 11, 2026, 9:20 PM EDT
Completed Not applicable Interventional Results available

SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System

NCT02439775
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions
Symplicity Spyral™ multi-electrode renal denervation system, Sham Procedure
Device · Procedure
Lead sponsor
Medtronic Vascular
Industry
Eligibility
20 Years to 80 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
32
States / cities
Huntsville, Alabama • Stanford, California • New Haven, Connecticut + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 11, 2026, 9:20 PM EDT
Completed Early Phase 1 Interventional

Physiological Study of the Efficacy and Mechanistic Effects of Alcohol Renal Denervation

NCT03465917
View directory record Official record
Conditions
Hypertension
Interventions
Renal Denervation
Combination Product
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Sep 11, 2026, 9:20 PM EDT
Recruiting No phase listed Observational

The RADIANCE CED Study

NCT07231757
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions
Ultrasound Renal Denervation (Paradise™ Ultrasound Renal Denervation (uRDN) System)
Device
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
65 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 11, 2026, 9:20 PM EDT
Recruiting Not applicable Interventional

Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension

NCT06526858
View directory record Official record
Conditions
Resistant Hypertension
Interventions
HyperQureTM Renal Denervation (RDN) System:
Device
Lead sponsor
DeepQure Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
Orange, California • Stanford, California • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 11, 2026, 9:20 PM EDT
Not listed Phase 2 Interventional

Comparison of Redo PVI With vs. Without Renal Denervation for Recurrent AF After Initial PVI

NCT01959997
View directory record Official record
Conditions
Atrial Fibrillation, Arterial Hypertension
Interventions
Redo PVI, PVI + RDN
Procedure
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Network
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Sep 11, 2026, 9:20 PM EDT
Recruiting Not applicable Interventional

THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension

NCT06559891
View directory record Official record
Conditions
Hypertension
Interventions
TIVUS™ Renal Denervation System, Sham
Device · Other
Lead sponsor
SoniVie Inc.
Industry
Eligibility
22 Years to 75 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 11, 2026, 9:20 PM EDT
Active, not recruiting Not applicable Interventional

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

NCT05198674
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Interventions
Renal Denervation (Symplicity Spyral™)
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
1,899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
77
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 11, 2026, 9:20 PM EDT
Recruiting Not applicable Interventional

SPYRAL GEMINI Pilot Study

NCT06907147
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Interventions
Multi-Organ Denervation Gemini System
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Stanford, California • Orlando, Florida • Safety Harbor, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 11, 2026, 9:20 PM EDT
Active, not recruiting Not applicable Interventional Results available

A Study of the ReCor Medical Paradise System in Clinical Hypertension

NCT02649426
View directory record Official record
Conditions
Hypertension, Vascular Diseases
Interventions
The Paradise® Renal Denervation Ultrasound System, Sham Procedure
Device
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 11, 2026, 9:20 PM EDT
Not yet recruiting Phase 3 Interventional

Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)

NCT07083765
View directory record Official record
Conditions
Hypertension, Hypertension,Essential
Interventions
Dehydrated Alcohol Injection, USP, Sham procedure
Drug · Procedure
Lead sponsor
Ablative Solutions, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 11, 2026, 9:20 PM EDT
Withdrawn Not applicable Interventional

Combined Afib Ablation and RA Denervation for the Maintenance of Sinus Rhythm and Management of Resistant Hypertension

NCT01952925
View directory record Official record
Conditions
Afib, Hypertension
Interventions
Renal Artery denervation
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Sep 11, 2026, 9:20 PM EDT
Active, not recruiting Not applicable Interventional

The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

NCT03614260
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions
Paradise Renal Denervation System, Renal Angiogram
Device · Procedure
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • Bridgeport, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 11, 2026, 9:20 PM EDT
Completed Phase 2 Interventional

Combined Treatment of Resistant Hypertension and Atrial Fibrillation

NCT01117025
View directory record Official record
Conditions
Hypertension, Resistant to Conventional Therapy, Atrial Fibrillation
Interventions
Circumferential PV isolation, Circumferential PVI+renal denervation
Procedure
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Network
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Sep 11, 2026, 9:20 PM EDT
Completed Not applicable Interventional Results available

SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study

NCT02439749
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions
Symplicity Spyral™ multi-electrode renal denervation system, Sham Procedure
Device · Procedure
Lead sponsor
Medtronic Vascular
Industry
Eligibility
20 Years to 80 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
30
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 11, 2026, 9:20 PM EDT
Completed Not applicable Interventional Results available

Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation

NCT02064764
View directory record Official record
Conditions
Atrial Fibrillation, Hypertension
Interventions
Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter, Arctic Front Advance™ Cardiac Cryoablation System
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
9
States / cities
Sacramento, California • Burlington, Massachusetts • Marquette, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Sep 11, 2026, 9:20 PM EDT
Completed Not applicable Interventional Results available

Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)

NCT02392351
View directory record Official record
Conditions
Hypertension
Interventions
Renal Denervation (Vessix), Renal Angiography
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Miami Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 11, 2026, 9:20 PM EDT
Active, not recruiting Not applicable Interventional

RADIANCE Continued Access Protocol

NCT05017935
View directory record Official record
Conditions
Hypertension, Hypertension, Resistant to Conventional Therapy, Vascular Diseases, Cardiovascular Diseases
Interventions
Renal Denervation
Device
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
40
States / cities
Chula Vista, California • Los Angeles, California • Sacramento, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2024 · Synced Sep 11, 2026, 9:20 PM EDT
Terminated Not applicable Interventional Results available

EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension

NCT01903187
View directory record Official record
Conditions
Hypertension
Interventions
EnligHTN Renal Denervation, Sham
Device · Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 11, 2026, 9:20 PM EDT
Not listed No phase listed Observational

Association Between a Multi-Gene Panel and Renal Denervation Effectiveness in Patients With Hypertension

NCT04060641
View directory record Official record
Conditions
Hypertension
Interventions
Geneticure for RDN Genetic Panel
Genetic
Lead sponsor
Geneticure, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Sep 11, 2026, 9:20 PM EDT